Can cancer survivorship models help clinicians navigate the road ahead with their cancer patients? Here to share insights on unmet needs, opportunities, and symptom burden for cancer survivorship care is Dr. Michelle Mollica, the Deputy Director at the National Cancer Institute’s Office of Cancer Survivorship.

The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.

To learn more about key considerations for prehabilitation, Nurse Practitioner Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio recaps important factors to keep in mind for cancer patients undergoing surgery.

When considering prehabilitation for cancer patients about to undergo surgery, what factors should we keep in mind? Nurse Practitioner Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio explores some of the key considerations involved in prehabilitation.

For some cancer patients undergoing surgery, prehabilitation care could impact their outcomes. So what do nurses need to consider in their preoperative assessment? And what key players are part of the multidisciplinary healthcare team? Lisa Parks from the Ohio State University Wexner Medical Center in Columbus, Ohio explores key factors for cancer surgery.

What are the current treatment options available for paroxysmal nocturnal hemoglobinuria (PNH), and how can we select the appropriate option based on various factors like efficacy, safety, and patient access? Joining Dr. Charles Turck in this important discussion is Dr. Brian Mulherin from Hematology Oncology of Indiana and Ascension St. Vincent Hospital in Indianapolis.

The goal of a clinician who is working with a patient who has paroxysmal nocturnal hemoglobinuria (PNH) is to improve their overall quality of life. So what approach can we use to address suboptimal patient outcomes? Join Dr. Charles Turck as he guides us through this PNH journey with Dr. David Dingli, Professor of Medicine in the Department of Hematology at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota.

The most common way for clinicians to detect paroxysmal nocturnal hemoglobinuria (PNH) in a patient are signs of intravascular hemolysis. So how does this disorder impact a patient’s quality of life? Dive in as Dr. Charles Turck is joined by Dr. Kubal, Associate Member in the Moffitt Cancer Center Malignant Hematology Department in Tampa, Florida, and Dr. Safah, Professor of Clinical Medicine at the Tulane University School of Medicine in New Orleans.

It's not uncommon for years to elapse after a patient first develops symptoms of paroxysmal nocturnal hemoglobinuria (PNH) and before a formal diagnosis is made. So how does the burden of PNH affect patient outcomes? Dive in as Dr. Charles Turck is joined by Dr. Brian Mulherin, Hematology and Oncology Specialist at Hematology Oncology of Indiana.

While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.